Core Insights - Oncternal Therapeutics, Inc. has sold its zilovertamab and ONCT-808 programs to Ho'ola Therapeutics, Inc. [1][2] - Zilovertamab is an investigational monoclonal antibody targeting ROR1, while ONCT-808 is a CAR T cell therapy that also targets ROR1 [1] - The asset sale was completed on June 27, 2025, under an asset purchase agreement [2] Financial Details - Ho'ola Therapeutics will pay Oncternal a total of $3.0 million upfront, with $2.25 million paid immediately and $750,000 contingent on resolving certain contractual obligations [2] - Oncternal is eligible for up to $65.0 million in milestone payments related to development, regulatory approval, and sales [2] - Development milestones include up to $5.0 million for pivotal clinical trial enrollment or regulatory submission, and regulatory milestones consist of up to $40.0 million for approvals [2] Management Changes - Following the asset sale, Craig R. Jalbert has been appointed as President, CEO, Treasurer, Secretary, and sole board member of Oncternal [2] - Jalbert has over 30 years of experience in overseeing company dissolutions and will manage the winddown of Oncternal's operations [2]